Treatment for Chronic Hepatitis B:
Experimental Mono- and Combination Therapies

Monotherapy Studies

EFFECT OF CORE PROMOTER/PRECORE MUTATION PATTERN AND EARLY VIROLOGIC RESPONSE ON EFFICACY OUTCOMES WITH TELBIVUDINE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B
N Naoumov. Abstract 747.

SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF PRADEFOVIR MESYLATE IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION: 48-WEEK ANALYSIS OF A PHASE 2 STUDY
K S Lee. Abstract 741.

ENOFOVIR (TNV) HAS STRONGER ANTIVIRAL EFFECT THAN ADEFOVIR DIPIVOXIL (ADV) AGAINST LAMIVUDINE (LAM) RESISTANT HEPATITIS B VIRUS (HBV).
H W Hann. Abstract 495.

PHASE II, MULTI-CENTRE, DOSE-ESCALATING STUDY OF LB80380 (ANA380) IN HEPATITIS B PATIENTS WITH LAMIVUDINE-RESISTANT YMDD MUTANT HBV  
C L Lai. Abstract 6.

ONE-YEAR TREATMENT WITH CLEVUDINE DEMONSTRATED SIGNIFICANT VIRAL SUPPRESSION AND BIOCHEMICAL IMPROVEMENT  
Y H Chung. Abstract 53.

PHASE III COMPARISON OF TELBIVUDINE VS LAMIVUDINE IN HBEAG-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B: EFFICACY, SAFETY, AND PREDICTORS OF RESPONSE AT 1 YEAR.   
E Gane. Abstract 493.   

HBV RESISTANCE DETERMINATION FROM THE TELBIVUDINE GLOBE REGISTRATION TRIAL
D N Standring. Abstract 514.                                                        

PREDICTING LIVER DISEASE COMPLICATIONS (HCC AND CIRRHOSIS) IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION USING A RISK FUNCTION MODEL: THE R.E.V.E.A.L.- HBV STUDY .
C-J Chen. Abstract 489.

TELBIVUDINE PRECLINICAL SAFETY STUDIES SUGGEST MINIMAL RISK OF CHRONIC TOXICITY, REPRODUCTIVE TOXICITY OR CARCINOGENICITY.
E Bridges. Abstract 388.

HBV RESISTANCE DETERMINATION FROM THE TELBIVUDINE GLOBE REGISTRATION TRIAL.
 D N Standring. Abstract 514.

Combination Therapy Studies

EFFECTS OF ENTECAVIR AND LAMIVUDINE ON ADVANCED LIVER FIBROSIS AFTER 48 WEEKS OF TREATMENT IN PATIENTS WITH CHB INFECTION: RESULTS OF THREE PIVOTAL TRIALS  
H Simsek. Abstract 513.

ABSENCE OF PHARMACOKINETIC DRUG-DRUG INTERACTION BETWEEN TELBIVUDINE AND PEGINTERFERON ALFA-2A OR CYCLOSPORINE IN HEALTHY SUBJECTS.
X J Zhou. Abstract 522.

EARLY HEPATITIS B VIRAL DYNAMICS AND END OF TREATMENT VIROLOGICAL RESPONSE (ETVR) IN CHRONIC HEPATITIS B/ HBEAG (-) PATIENTS RECEIVING PEGYLATED INTERFERON ALFA-2B AND/OR LAMIVUDINE  
T Vassiliadis. Abstract 517.

48 WEEKS OF ADEFOVIR MONOTHERAPY FOLLOWING 48 WEEKS OF COMBINATION THERAPY WITH PEGINTERFERON ALFA-2B AND ADEFOVIR LEADS TO ADDITIONAL BIOCHEMICAL AND VIROLOGICAL IMPROVEMENT  
M Lutgehetmann. Abstract 508.  

NO EVIDENCE FOR ADV RESISTANCE IN HBEAG-NEGATIVE LAMIVUDINE RESISTANT PATIENTS TREATED WITH LAMIVUDINE-ADEFOVIR COMBINATION FOR 3 YEARS.
P Lampertico. Abstract 499. 

CONVERSION OF LIVER TRANSPLANT RECIPIENTS WITH HEPATITIS B VIRUS FROM HEPATITIS B IMMUNE GLOBULIN (HBIG) AND LAMIVUDINE (LAM) TO ADEFOVIR DIPIVOXIL (ADV) AND LAM
G W Neff. Abstract 505.

Experimental Treatments: Miscellaneous

A NOVEL PRIMEBOOST THERAPEUTIC VACCINE INDUCES SUSTAINED SEROCONVERSION AT 52 WEEKS IN PATIENTS WITH HBEAG+ CHRONIC HEPATITIS B: A PHASE IIA CLINICAL TRIAL
J Schneider. Abstract 749.

CIRRHOSIS REVERSAL BY ANTIFIBROTIC COMBINATION THERAPY: POTENTIATION OF THE ANTIFIBROTIC EFFECT OF MYCOPHENOLATE MOFETIL BY PIOGLITAZONE AND HALOFUGINONE.
Y Popov. Abstract 194.

THE ROLE OF HBV OCCULT INFECTION IN PATIENTS WITH NON-HODGKIN LYMPHOMA: PREVALENCE AND TREATMENT OPTIONS WITH NUCLEOTIDES ANALOGUES
M Persico. Abstract 507.